RS59435B1 - Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije - Google Patents

Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije

Info

Publication number
RS59435B1
RS59435B1 RSP20191351A RS59435B1 RS 59435 B1 RS59435 B1 RS 59435B1 RS P20191351 A RSP20191351 A RS P20191351A RS 59435 B1 RS59435 B1 RS 59435B1
Authority
RS
Serbia
Prior art keywords
purin
methyl
amino
compound
oxo
Prior art date
Application number
Other languages
English (en)
Serbian (sr)
Inventor
Chungen Liang
Kun Miao
Jianping Wang
Hongying Yun
Xiufang Zheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59435(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS59435B1 publication Critical patent/RS59435B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RSP20191351 2015-05-08 2016-05-04 Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije RS59435B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EP16720421.3A EP3294740B1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
RS59435B1 true RS59435B1 (sr) 2019-11-29

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP20191351 RS59435B1 (sr) 2015-05-08 2016-05-04 Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije

Country Status (32)

Country Link
US (3) US9708325B2 (https=)
EP (1) EP3294740B1 (https=)
JP (1) JP6738352B2 (https=)
KR (1) KR102690131B1 (https=)
CN (1) CN107580596B (https=)
AR (1) AR104528A1 (https=)
AU (3) AU2016260683B2 (https=)
BR (1) BR112017023959B1 (https=)
CA (1) CA2982704C (https=)
CL (1) CL2017002745A1 (https=)
CO (1) CO2017009994A2 (https=)
CR (1) CR20170496A (https=)
DK (1) DK3294740T3 (https=)
ES (1) ES2753777T3 (https=)
HR (1) HRP20191942T1 (https=)
HU (1) HUE045906T2 (https=)
IL (2) IL254947B (https=)
LT (1) LT3294740T (https=)
MX (2) MX393198B (https=)
MY (1) MY182353A (https=)
NZ (2) NZ775222A (https=)
PE (1) PE20171620A1 (https=)
PH (1) PH12017502009A1 (https=)
PL (1) PL3294740T3 (https=)
PT (1) PT3294740T (https=)
RS (1) RS59435B1 (https=)
RU (1) RU2745269C2 (https=)
SG (1) SG10202108841YA (https=)
SI (1) SI3294740T1 (https=)
TW (2) TWI706954B (https=)
UA (1) UA120450C2 (https=)
WO (1) WO2016180695A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294740T3 (pl) 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych
EP3512556B1 (en) 2016-09-13 2021-08-18 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
JP7089596B2 (ja) * 2018-02-28 2022-06-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための7位置換スルホンイミドイルプリノン化合物及び誘導体
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CA3128081A1 (en) * 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US12503461B2 (en) 2019-09-20 2025-12-23 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097105A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2006242920A1 (en) * 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
CN110590809B (zh) 2013-03-29 2022-04-19 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
HRP20210927T1 (hr) 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Also Published As

Publication number Publication date
HUE045906T2 (hu) 2020-01-28
CL2017002745A1 (es) 2018-05-18
BR112017023959A2 (pt) 2018-07-17
TWI768467B (zh) 2022-06-21
US20160326177A1 (en) 2016-11-10
SG10202108841YA (en) 2021-09-29
JP2018515509A (ja) 2018-06-14
HRP20191942T1 (hr) 2020-01-10
NZ775222A (en) 2024-09-27
SI3294740T1 (sl) 2019-12-31
PH12017502009A1 (en) 2018-03-26
AU2020256348B2 (en) 2022-06-16
MX2017014033A (es) 2018-03-01
WO2016180695A1 (en) 2016-11-17
JP6738352B2 (ja) 2020-08-12
BR112017023959B1 (pt) 2023-05-02
RU2017142577A3 (https=) 2019-10-31
CN107580596B (zh) 2020-07-14
ES2753777T3 (es) 2020-04-14
DK3294740T3 (da) 2019-11-04
TWI706954B (zh) 2020-10-11
AR104528A1 (es) 2017-07-26
US20170275286A1 (en) 2017-09-28
IL254947B (en) 2021-02-28
PL3294740T3 (pl) 2020-03-31
US9708325B2 (en) 2017-07-18
NZ735648A (en) 2023-06-30
PT3294740T (pt) 2019-10-29
AU2016260683B2 (en) 2020-10-29
AU2022204666A1 (en) 2022-07-21
EP3294740A1 (en) 2018-03-21
MX2020010949A (es) 2022-06-16
PE20171620A1 (es) 2017-11-02
HK1247925A1 (zh) 2018-10-05
CA2982704A1 (en) 2016-11-17
KR20180003612A (ko) 2018-01-09
RU2017142577A (ru) 2019-06-10
AU2016260683A1 (en) 2017-10-12
US20200109144A1 (en) 2020-04-09
MX376761B (es) 2025-03-07
US10399983B2 (en) 2019-09-03
IL254947A0 (en) 2017-12-31
MY182353A (en) 2021-01-20
TW201716410A (zh) 2017-05-16
CN107580596A (zh) 2018-01-12
IL280769B2 (en) 2023-07-01
AU2020256348A1 (en) 2020-11-12
KR102690131B1 (ko) 2024-07-31
UA120450C2 (uk) 2019-12-10
CO2017009994A2 (es) 2018-02-20
US11242345B2 (en) 2022-02-08
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
IL280769B1 (en) 2023-03-01
CA2982704C (en) 2023-10-24
CR20170496A (es) 2017-12-05
MX393198B (es) 2025-03-19
IL280769A (en) 2021-04-29
EP3294740B1 (en) 2019-09-04
LT3294740T (lt) 2019-11-25

Similar Documents

Publication Publication Date Title
US11242345B2 (en) Sulfonimidoylpurinone compounds and methods of treatment using the same
JP7654643B2 (ja) ホスホジエステラーゼ阻害剤および使用
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
RU2540332C2 (ru) Бициклические азотсодержащие гетероциклические соединения, полезные при лечении гепатита с
RU2380101C2 (ru) Бициклические пиримидины, ингибирующие hcv
AU2006315334B2 (en) Aminopyrimidines useful as kinase inhibitors
JP7749602B2 (ja) アミドピリミドン誘導体
BRPI0619704A2 (pt) composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar um distúrbio proliferativo e método para tratar cáncer
KR20100116206A (ko) Hsp90 저해제로서의 옥심 유도체
AU2008240313A1 (en) Aminopyrimidines useful as kinase inhibitors
CN114450277A (zh) 用于治疗和预防乙型肝炎病毒感染的经取代的嘧啶
HK1247925B (zh) 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
HK40067638A (en) Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
CN117715911A (zh) 癌症治疗中的n6-腺苷-甲基转移酶抑制剂